Omeros (OMER) Current Deferred Revenue (2010 - 2026)

Omeros (OMER) reported Current Deferred Revenue of $2.8 million for Q1 2026, up 13.99% sequentially from $2.5 million in Q4 2025.

Omeros (OMER) Current Deferred Revenue (2010 - 2026) Analysis & Trends

Omeros (OMER) has 9 years of Current Deferred Revenue data on file, last reported at $2.8 million in Q1 2026.

For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (changed N/A YoY), and the FY2025 full-year result was $2.5 million, up 1251.37% from the prior year.
Current Deferred Revenue grew to $2.8 million in Q1 2026, from $2.5 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $2.8 million in Q1 2026 to a low of $183000.0 in Q4 2024.
A 3-year average of $1.8 million and a median of $2.5 million in 2025 frame the typical range for Current Deferred Revenue.
Peak annual rise in Current Deferred Revenue reached 1251.37% in 2025, while the deepest fall reached 1251.37% in 2025.
Tracing OMER's Current Deferred Revenue over 3 years: stood at $183000.0 in 2024, then soared by 1251.37% to $2.5 million in 2025, then grew by 13.99% to $2.8 million in 2026.
Business Quant data shows OMER's Current Deferred Revenue at $2.8 million in Q1 2026, $2.5 million in Q4 2025, and $183000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn

Download Data